{"id":103740,"date":"2026-11-20T15:21:39","date_gmt":"2026-11-20T15:21:39","guid":{"rendered":"https:\/\/newsvog.com\/ur\/103740"},"modified":"2026-11-20T15:21:40","modified_gmt":"2026-11-20T15:21:40","slug":"ai-speeds-up-drug-discovery-as-big-pharma-eyes-anthropic","status":"publish","type":"post","link":"https:\/\/newsvog.com\/ur\/103740","title":{"rendered":"AI Speeds Up Drug Discovery as Big Pharma Eyes Anthropic"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div style=\"font-size:16px;line-height:1.6\">\n<p><strong>NEW YORK: Artificial intelligence has sped up early-stage drug development work at some of the world\u2019s largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic, according to their \u200btop scientists.<\/strong><\/p>\n<p>GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi all say they have moved beyond less glamorous tasks for AI like preparing regulatory filings. They are now using the technology for \u200cdesigning molecules, sorting out the most promising ones, and identifying safety risks.<\/p>\n<p>\u201cThere is no part of the discovery through development pipeline where we are not using AI,\u201d AstraZeneca executive Sharon Barr said.<\/p>\n<p>Some of the scientists say decades of drug discovery experience and data give them an advantage over AI companies like Anthropic, which is gearing up to be a rival, partner or both, with a $1.5 trillion initial public offering this week.<\/p>\n<p>In recent months, it opened its own laboratory and announced other investments, part of pushing AI to speed drug discovery.<\/p>\n<p>On Thursday, Anthropic CEO Dario Amodei, at the Nasdaq before shares began trading, \u200bspoke of his father dying of a disease shortly before a cure was found.<\/p>\n<p>Although clinical trials and experiments will still take time, he said, \u201cI believe these processes can be substantially accelerated by AI. We hope that in the future, fewer \u200bfamilies miss a cure by a few years.\u201d<\/p>\n<p>Drug companies are gauging whether the upstart can succeed in tackling disease. Historically, nearly 9 out of 10 drugs developed using conventional methods fail ?in clinical trials. It can cost billions of dollars and take 10 to 15 years to bring a drug to market, according to industry lobby group PhRMA.<\/p>\n<p>Aliza Apple, who runs Lilly\u2019s TuneLab, which gives smaller biotechs access to some of the drugmaker\u2019s internal \u200bAI models to promote collaboration, said claims like those made by Amodei and the founders of Alphabet\u2019s Isomorphic Labs that the technology is capable of curing all disease overstate current capabilities.<\/p>\n<p>The scale of extinction of plants and fungi is likely to be underestimated, \u201cIt would be great for them to cure one, and then let\u2019s talk about the \u200brest,\u201d she said.<\/p>\n<h2>CONCRETE RESULTS<\/h2>\n<p>Pharma company scientists say their AI programs are already yielding concrete results.<\/p>\n<p>Sanofi said it saved at least a year developing asthma treatment lunsekimig using an AI-enabled approach to translate early biology into clinical decisions that let the company skip a dose-selection study. Novartis said AI tools helped it find five targets it prioritized for developing kidney disease treatments.<\/p>\n<p>Bristol Myers said one of its sickle cell anemia candidates would not have been developed without the company\u2019s AI systems. It\u2019s using AI to refine new molecules and run simulations based on its trial data to determine which ones should \u200bprogress, Chief Research Officer Robert Plenge said.<\/p>\n<p>\u201cThe next area for us is to tie those models into laboratory automation\u2026 to make better, high-quality molecules faster,\u201d he added.<\/p>\n<p>Novo Nordisk said AI has cut the number of cycles of designing, manufacturing and testing new molecules \u200bfrom around eight to three and slashed the time of each cycle from eight weeks to four.<\/p>\n<p>Still, the number of AI-enabled drugs in clinical testing has only climbed incrementally. In March, researchers identified 129 drug candidates across 69 companies, up from around 117 eight months earlier. Most of \u200cthe programs remain ?in early-stage development.<\/p>\n<p>\u201cI think over the next 1, 2, 3 years we\u2019ll see a sharp uptick in AI drugs being developed pre-clinically and also drugs that go to clinical trials,\u201d said Dr. Waqas Haque, an oncology fellow at University of Chicago who was on the team that compiled the data.<\/p>\n<p>\u201cI don\u2019t know if those drugs are going to be more successful than non-AI drugs, and I don\u2019t think they\u2019re going to be approved any quicker,\u201d he said, because of bottlenecks with human trials and regulators.<\/p>\n<h2>\u2018JUST THE BEGINNING\u2019<\/h2>\n<p>Anthropic\u2019s Amodei has long said curing disease is one of the main benefits AI can provide to humanity.<\/p>\n<p>The company is working on its own and with partners like Bristol Myers to develop new drugs. It launched scientific research-focused AI software called Claude Science, and added Novartis CEO \u200bVas Narasimhan to its board. Other companies, including Novo Nordisk, use \u200bAnthropic models and Claude Science in their R&amp;D work.<\/p>\n<p>Luca Giani, ?senior principal at venture capital firm Alumni Ventures, said Anthropic \u2014 and rival frontier labs \u2014 are shopping for pharma-related acquisitions.<\/p>\n<p>\u201cThey are out to get more data, and they are out to get more of the companies,\u201d Giani said.<\/p>\n<p>Anthropic did not respond to a request for comment on its acquisition plans and the nature of its relationship with drugmakers.<\/p>\n<p>Even before its $1.5 trillion IPO, Anthropic announced several partnerships and \u200ban acquisition last month, he said.<\/p>\n<p>\u201cI think it\u2019s just the beginning.\u201d<\/p>\n<p>Lilly\u2019s Apple said Anthropic and AI rivals can be viewed as allies and competitors.<\/p>\n<p>\u201cIn the early days, we certainly saw them \u200bas vendors. To be fair, that\u2019s ?how they framed themselves. I think we increasingly see them as collaborators,\u201d Apple said. \u201cA year ago they weren\u2019t doing any programs, and a year from now, it\u2019s anyone\u2019s guess.\u201d<\/p>\n<p>GSK Chief Scientific Officer Tony Wood said he views Anthropic \u201cas another competitor,\u201d while Bristol Myers and Novo see the AI companies more as partners.<\/p>\n<p>Still, Novo said it does not provide proprietary data to frontier labs to train their AI models, nor does Sanofi.<\/p>\n<p>\u201cIf you don\u2019t have the data to train the model on, then it breaks down very quickly,\u201d said Matt Truppo, global head of computational &amp; ?AI strategy for \u200bSanofi R&amp;D.<\/p>\n<p>Truppo said he expects AI to cut early-discovery timelines by 20% to 25% within two years, and perhaps by half within five years, across more \u200bthan 100 drug development programs.<\/p>\n<p>It may be some time before this can be expanded beyond treatment areas where the company has the most proprietary data, he added.<\/p>\n<p>Novartis President of Biomedical Research Fiona Marshall said the average time from project start to a drug candidate has gone from three years to about 18 months to \u200btwo years.<\/p>\n<p>\u201cWe have had a lot of data,\u201d Marshall said, \u201cand now we can really use that data in a much more sophisticated way.\u201d<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/arynews.tv\/big-pharma-with-eye-on-anthropic-says-ai-is-shrinking-drug-discovery-timelines\" target=\"_blank\" rel=\"noopener\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK: Artificial intelligence has sped up early-stage drug development work at some of the world\u2019s largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic, according to their \u200btop scientists. GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi all say&#8230;<\/p>\n","protected":false},"author":1,"featured_media":103741,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[16],"tags":[],"class_list":["post-103740","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pakistan"],"taxonomy_info":{"category":[{"value":16,"label":"Pakistan"}]},"featured_image_src_large":["https:\/\/newsvog.com\/ur\/wp-content\/uploads\/1795188100_Anthropic-7-1024x576.jpg",1024,576,true],"author_info":{"display_name":"frkhokhar@gmail.com","author_link":"https:\/\/newsvog.com\/ur\/author\/frkhokhargmail-com"},"comment_info":0,"category_info":[{"term_id":16,"name":"Pakistan","slug":"pakistan","term_group":0,"term_taxonomy_id":16,"taxonomy":"category","description":"All about Pakistan","parent":0,"count":11052,"filter":"raw","cat_ID":16,"category_count":11052,"category_description":"All about Pakistan","cat_name":"Pakistan","category_nicename":"pakistan","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/posts\/103740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/comments?post=103740"}],"version-history":[{"count":1,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/posts\/103740\/revisions"}],"predecessor-version":[{"id":103742,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/posts\/103740\/revisions\/103742"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/media\/103741"}],"wp:attachment":[{"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/media?parent=103740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/categories?post=103740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/tags?post=103740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}